GSK ' s Long-Acting Injection Beats Truvada in HIV Prevention Trial GSK ' s Long-Acting Injection Beats Truvada in HIV Prevention Trial

GSK said an injection every other month of its cabotegravir drug was shown to avert an HIV infection more effectively than Gilead ' s daily Truvada pill.Reuters Health Information
Source: Medscape Hiv-Aids Headlines - Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news